Hakim Yadi BioLeader Interview - Hakim Yadi, Chief Executive Officer & Co-Founder, Closed Loop Medicine (September 2022) Hakim is a Co-Founder and Chief Executive Officer of Closed Loop Medicine (CLM). CLM is a healthcare technology company developing drug + digital combination products, transforming drug effectiveness through optimisation by providing every drug its real time digital companion. Hakim joined Closed Loop Medicine from the Northern Health Science Alliance Ltd, the pan-Northern health partnership which brought together for the first time 20 research-based NHS hospitals, the North’s Academic Health Science Networks and Universities to collaborate on improving health outcomes across the [...]
Jorge Quiroz BioLeader Interview - Jorge Quiroz, Executive Vice President, Chief Medical Officer, NMD Pharma, Boston USA (September 2022) Dr. Quiroz brings twenty years of drug development experience in academic, pharmaceutical and biotechnology industries. He has been responsible for the scientific, clinical, and regulatory strategies across all phases of drug development, globally, including IND filings for rare disorders, and proof of concept and registrational studies for NDA and sNDA. He currently serves as a member of the Board of Directors of Perception Neurosciences and prior to NMD Pharma, Dr. Quiroz served as Chief Medical Officer of venture backed and [...]
Mandeep Dhillon BioLeader Interview - Mandeep Dhillon, KQ Labs Lead - Translation at The Francis Crick Institute (August 2022) Mandeep joined the Crick in 2022 to lead KQ Labs, an accelerator that is focused on supporting early-stage data-driven health start-ups. Prior to KQ Labs, Mandeep was a Partner and Head of Digital Health at BioScience Managers, a global life science venture capital firm. Before stepping into venture capital, Mandeep spent nearly a decade in Management Consulting. In his last role as Principal at Arthur D. Little, he led the Strategy Phase 0 team within the Digital Problem Solving Practice. [...]
It has been a highly productive summer period for PIR International, with growth across all facets of Life Sciences. We are pleased to share a selection of our recent appointments with our valued clients across the UK, Europe and the US.
Anders Tuv BioLeader Interview - Anders Tuv, Chief Investment Officer at Radforsk, Norway (May 2022) Anders is Chief Investment Officer of the life science investment company Radforsk, which is focused on immunotherapies and precision medicines. He is an experienced investment and business development professional in the life science industry. His roles and responsibilities cover management positions, strategy and business development, research collaborations, licensing deals, M&A and IPOs. Anders also holds several chairman and non-executive director positions. Key milestones in your career journey to date? My time as managing consultant at Ernst & Young Advisory, focused on the healthcare industry, [...]
Agnete Fredriksen BioLeader Interview - Agnete Fredriksen, Co-Founder, Chief Innovation & Strategy Officer at Nykode Therapeutics AS (April 2022) Agnete is a co-founder of Nykode Therapeutics and served as Chief Scientific Officer from 2007-2021, leading the organisation’s scientific strategy. Her previous employers include Affitech AS and Medinnova AS. She is the author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. Agnete holds an MSc and a Ph.D. from the Institute of Immunology, Rikshospitalet Medical Center in Oslo, where she designed and developed the first [...]
Camilla Simpson BioLeader Interview - Camilla Simpson, Chief Executive Officer, Zehna Therapeutics (April 2022) Camilla Simpson has over two decades of business and strategy experience across a diverse group of organizations: from seed investments to public companies. Camilla has demonstrated a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need throughout her career. Currently, Camilla is CEO of Zehna Therapeutics, Inc a seed stage startup and spin out of the Cleveland Clinic. Prior to this, Camilla founded Rare Strategic LLC where she provided strategic advice to early-stage [...]
Susan Hill BioLeader Interview - Susan Hill, Chief Executive Officer of Mestag Therapeutics and Venture Partner with SV Health Investors (February 2022) Susan Hill is founding Chief Executive Officer of Mestag Therapeutics, a Cambridge (UK)- based biotech company developing new therapeutics for inflammatory disease and cancer. Mestag explores the role of fibroblasts in influencing the immune environment in disease, supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company raised seed financing of $45m in 2021 and was recognized on the 2021 Fierce 15 list of [...]
It has been a highly productive recent period for PIR International, with growth across all facets of Life Sciences. We are pleased to share a selection of our recent appointments with our valued clients across the UK, Europe and the US.
The Board of PIR International, a leading provider of executive search and interim services to the global life science industry, today announced the finalisation of an MBO with the executive team of the business, Sally Hope, Stuart Penney, and Tom Bradley, who will acquire the majority of shares from the founder, Carolyn Douthwaite. Carolyn founded the business in 2006, initially focused on the provision of senior interims to major life science companies. Since then, the range of services has evolved, in line with client demand, and particularly the growth of the services to early stage, investor backed biotechs. This has [...]